Free Trial
→ I’m sounding the alarm (From Porter & Company) (Ad)tc pixel Free SLNO Stock Alerts

Soleno Therapeutics (SLNO) Financials

Soleno Therapeutics logo
$53.01 +0.00 (+0.01%)
Closing price 05/15/2026 07:41 PM Eastern
Extended Trading
$53.01 0.00 (0.00%)
As of 05/15/2026 07:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Soleno Therapeutics

Annual Income Statements for Soleno Therapeutics

This table shows Soleno Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -16 -16 -15 -13 -31 -25 -31 -24 -39 -176 20
Consolidated Net Income / (Loss)		 -16 -12 -15 -13 -31 -25 -31 -24 -39 -176 21
Net Income / (Loss) Continuing Operations		 -16 -6.74 -12 -12 -31 -25 -31 -24 -39 -176 21
Total Pre-Tax Income 		-16 -6.74 -13 -12 -31 -25 -31 -24 -39 -176 21
Total Operating Income		 -12 -8.32 -12 -14 -23 -36 -32 -24 -41 -188 9.41
Total Gross Profit		 0.25 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 188
Total Revenue		 0.61 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 190
Operating Revenue		 0.61 - - - - - - - 0.00 0.00 190
Total Cost of Revenue		 0.35 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.70
Operating Cost of Revenue		 0.35 - - - - - - - 0.00 0.00 2.70
Total Operating Expenses		 12 8.32 12 14 23 36 32 24 41 188 178
Selling, General & Admin Expense		 6.14 6.08 6.58 6.56 6.93 8.76 11 9.84 13 106 132
Research & Development Expense		 4.54 2.25 3.07 7.18 16 23 21 15 25 79 41
Other Operating Expenses / (Income)		 - - 2.49 0.57 0.29 4.34 -0.73 -0.71 2.71 3.24 5.54
Total Other Income / (Expense), net		 -3.75 1.59 -1.27 2.46 -7.29 12 0.62 0.33 2.40 12 11
Interest Expense		 - - - - - - - 0.00 0.00 0.23 5.48
Interest & Investment Income		 - - - 1.83 -0.48 - - 0.30 2.58 12 17
Other Income / (Expense), net		 -3.75 1.59 -1.27 0.63 -6.81 12 0.62 0.03 -0.18 0.00 0.00
Preferred Stock Dividends Declared		 0.00 3.65 - - - - - - 0.00 0.00 -0.42
Net Income / (Loss) Attributable to Noncontrolling Interest		 - - - - - - - - 0.00 0.00 -0.42
Basic Earnings per Share		 ($1.69) ($5.07) ($1.71) ($0.64) ($0.90) ($0.39) ($5.81) ($2.87) ($2.36) ($4.38) $0.40
Weighted Average Basic Shares Outstanding		 9.43M 3.10M 8.98M 20.98M 34.14M 62.62M 5.32M 8.40M 16.49M 40.18M 50.82M
Diluted Earnings per Share		 ($1.69) ($5.07) ($1.71) ($0.64) ($0.90) ($0.39) ($5.81) ($2.87) ($2.36) ($4.38) $0.39
Weighted Average Diluted Shares Outstanding		 9.43M 3.10M 8.98M 20.98M 34.14M 62.62M 5.32M 8.40M 16.49M 40.18M 52.38M
Weighted Average Basic & Diluted Shares Outstanding		 9.43M 3.10M 8.98M 20.98M 34.14M 62.62M 79.77M 8.17M 32.46M 45.86M 51.62M

Quarterly Income Statements for Soleno Therapeutics

This table shows Soleno Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -11 -11 -21 -22 -77 -56 -44 -4.71 26 43 31
Consolidated Net Income / (Loss)		 -11 -11 -21 -22 -77 -56 -44 -4.71 26 43 31
Net Income / (Loss) Continuing Operations		 -11 -11 -21 -22 -77 -56 -44 -4.71 26 43 31
Total Pre-Tax Income 		-11 -11 -21 -22 -77 -56 -44 -4.71 26 43 35
Total Operating Income		 -10 -14 -23 -25 -80 -59 -46 -6.53 22 40 31
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 32 65 91 93
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 33 66 92 95
Operating Revenue		 - - - 0.00 0.00 - 0.00 33 66 - 95
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.70 1.14 0.86 1.20
Operating Cost of Revenue		 - - - 0.00 0.00 - 0.00 0.70 1.14 - 1.20
Total Operating Expenses		 10 14 23 25 80 59 46 38 43 51 62
Selling, General & Admin Expense		 3.32 4.14 8.47 11 49 37 29 28 34 41 50
Research & Development Expense		 6.04 8.69 15 12 30 21 14 9.15 8.41 9.56 11
Other Operating Expenses / (Income)		 1.02 1.08 0.40 1.64 0.88 0.33 2.97 1.10 0.61 0.85 0.48
Total Other Income / (Expense), net		 -0.48 2.61 2.08 3.01 3.60 3.13 1.97 1.82 3.91 3.78 3.64
Interest Expense		 - - 0.00 0.00 0.00 - 1.36 1.38 1.39 1.35 1.29
Interest & Investment Income		 0.17 2.14 2.08 3.01 3.60 3.37 3.33 3.19 5.30 5.13 4.93
Income Tax Expense		 - - - - - - 0.00 - - - 3.54
Preferred Stock Dividends Declared		 - - - - - - 0.00 - - - -0.00
Net Income / (Loss) Attributable to Noncontrolling Interest		 - - - - - - 0.00 - - - -0.00
Basic Earnings per Share		 ($0.95) $0.28 ($0.59) ($0.57) ($1.83) ($1.39) ($0.95) ($0.09) $0.49 $0.95 $0.60
Weighted Average Basic Shares Outstanding		 11.44M 16.49M 36.21M 38.63M 41.88M 40.18M 46.18M 50.48M 53.33M 50.82M 52.09M
Diluted Earnings per Share		 ($0.95) $0.28 ($0.59) ($0.57) ($1.83) ($1.39) ($0.95) ($0.09) $0.47 $0.96 $0.59
Weighted Average Diluted Shares Outstanding		 11.44M 16.49M 36.21M 38.63M 41.88M 40.18M 46.18M 50.48M 54.92M 52.38M 53.07M
Weighted Average Basic & Diluted Shares Outstanding		 30.50M 32.46M 33.41M 38.87M 43.12M 45.86M 50.39M 53.15M 53.71M 51.62M 52.12M

Annual Cash Flow Statements for Soleno Therapeutics

This table details how cash moves in and out of Soleno Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -2.46 -2.50 14 5.96 -2.37 28 -28 -6.70 155 -82 -18
Net Cash From Operating Activities		 -10 -13 -9.95 -12 -17 -25 -28 -21 -25 -69 47
Net Cash From Continuing Operating Activities		 -10 -7.26 -6.92 -10 -17 -25 -28 -21 -25 -69 47
Net Income / (Loss) Continuing Operations		 -16 -6.74 -15 -12 -31 -25 -31 -24 -39 -176 21
Consolidated Net Income / (Loss)		 -16 -12 -15 -13 -31 -25 -31 -24 -39 -176 21
Depreciation Expense		 0.11 0.02 1.61 1.96 1.96 1.95 1.96 1.96 1.96 1.99 2.02
Amortization Expense		 - - - - - - - 0.00 0.00 -4.90 -3.48
Non-Cash Adjustments To Reconcile Net Income		 4.69 -0.90 6.04 -0.77 11 -8.06 1.96 1.88 9.16 104 52
Changes in Operating Assets and Liabilities, net		 0.81 0.36 0.82 0.33 0.82 5.53 -0.78 -0.56 2.93 6.20 -25
Net Cash From Investing Activities		 -1.32 -0.04 0.15 -0.18 0.53 -0.01 -0.02 -0.01 0.00 -226 -202
Net Cash From Continuing Investing Activities		 -1.32 -0.01 -0.56 -0.01 0.53 -0.01 -0.02 -0.01 0.00 -226 -202
Purchase of Property, Plant & Equipment		 -0.06 -0.01 -0.58 -0.01 -0.02 -0.01 -0.02 -0.01 0.00 -0.22 -0.07
Purchase of Investments		 - - - - - - - 0.00 0.00 -356 -456
Sale and/or Maturity of Investments		 - - - - - - - 0.00 0.00 131 254
Net Cash From Financing Activities		 9.16 11 24 18 14 54 -0.13 14 180 213 137
Net Cash From Continuing Financing Activities		 5.21 11 24 16 14 54 -0.13 14 180 213 137
Repayment of Debt		 - - - - - - - - 0.00 0.00 -0.06
Repurchase of Common Equity		 - - - - - - 0.00 - 0.00 0.00 -100
Issuance of Debt		 0.10 - - - - - - 0.00 0.00 50 0.00
Issuance of Common Equity		 2.01 0.00 25 16 14 54 0.00 14 138 162 216
Other Financing Activities, net		 0.37 -0.05 -1.06 - 0.00 0.00 -0.13 -0.02 42 1.32 22
Cash Interest Paid		 - - - - - - - - 0.00 0.21 4.53

Quarterly Cash Flow Statements for Soleno Therapeutics

This table details how cash moves in and out of Soleno Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 33 117 -127 14 -8.61 40 -6.60 -4.83 170 -177 63
Net Cash From Operating Activities		 -6.33 -6.31 -13 -18 -15 -24 -33 -13 43 49 26
Net Cash From Continuing Operating Activities		 -6.33 -6.31 -13 -18 -15 -24 -33 -13 43 49 26
Net Income / (Loss) Continuing Operations		 -11 -11 -21 -22 -77 -56 -44 -4.71 26 43 31
Consolidated Net Income / (Loss)		 -11 -11 -21 -22 -77 -56 -44 -4.71 26 43 31
Depreciation Expense		 0.49 0.49 0.49 0.49 0.50 0.50 0.50 0.50 0.50 0.51 0.51
Amortization Expense		 - - -0.47 -1.11 -1.91 -1.40 -0.97 -0.97 -0.36 -1.18 -0.21
Non-Cash Adjustments To Reconcile Net Income		 3.71 2.74 5.92 8.34 57 30 18 11 11 12 14
Changes in Operating Assets and Liabilities, net		 0.33 1.75 2.94 -3.51 5.61 2.55 -6.36 -18 6.59 -6.42 -19
Net Cash From Investing Activities		 - - -115 -121 4.04 6.44 23 -7.92 -91 -125 38
Net Cash From Continuing Investing Activities		 - - -115 -121 4.04 6.44 23 -7.92 -91 -125 38
Purchase of Property, Plant & Equipment		 - - -0.01 -0.01 -0.19 -0.01 -0.01 -0.01 -0.00 -0.06 -0.04
Purchase of Investments		 - - -115 -146 -48 -48 -45 -59 -163 -188 -101
Sale and/or Maturity of Investments		 - - 0.00 - 52 54 68 52 72 63 139
Net Cash From Financing Activities		 39 124 0.94 153 2.28 57 3.22 16 218 -100 -1.04
Net Cash From Continuing Financing Activities		 39 124 0.94 153 2.28 57 3.22 16 218 -100 -1.04
Repayment of Debt		 - - 0.00 - - - -0.06 - - - 0.00
Repurchase of Common Equity		 - - - - - - 0.00 - - - -0.00
Other Financing Activities, net		 0.01 42 0.94 3.16 -2.78 13 3.28 16 2.26 0.25 -1.04
Cash Interest Paid		 - - 0.00 - - - 0.81 1.26 1.26 1.22 1.16

Annual Balance Sheets for Soleno Therapeutics

This table presents Soleno Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 8.20 5.56 39 43 38 65 36 26 181 331 564
Total Current Assets		 6.40 3.80 18 25 21 50 22 16 171 294 356
Cash & Equivalents		 5.49 2.73 17 23 21 49 21 15 170 88 70
Short-Term Investments		 - - - 0.98 - - - - 0.00 204 235
Accounts Receivable		 0.16 - - 0.06 - - - - - 0.00 28
Inventories, net		 0.55 - - - - - - - - 0.00 15
Prepaid Expenses		 0.17 0.25 0.34 0.53 0.41 1.02 1.12 1.05 1.68 2.45 7.11
Plant, Property, & Equipment, net		 0.09 0.04 0.02 0.01 0.02 0.02 0.03 0.03 0.01 0.19 0.19
Total Noncurrent Assets		 1.71 1.72 21 18 17 15 13 11 9.32 37 208
Long-Term Investments		 - - - - - - - - 0.00 27 201
Intangible Assets		 0.08 - 20 18 17 15 13 11 8.75 6.81 4.86
Other Noncurrent Operating Assets		 0.72 0.13 0.13 - 0.46 0.12 0.46 0.13 0.57 2.88 2.35
Total Liabilities & Shareholders' Equity		 8.20 5.56 39 43 38 65 36 26 181 331 564
Total Liabilities		 4.98 2.13 12 13 23 19 18 16 23 86 114
Total Current Liabilities		 3.19 1.71 1.73 1.88 4.96 8.62 8.01 7.31 12 19 61
Accounts Payable		 0.70 0.41 0.63 0.93 2.00 3.49 3.25 1.78 3.15 8.88 12
Current Employee Benefit Liabilities		 - - - 0.27 0.28 1.01 0.73 1.68 3.14 4.78 9.68
Other Current Liabilities		 0.87 - - 0.35 0.69 0.34 0.61 0.64 1.83 5.09 39
Total Noncurrent Liabilities		 1.78 0.42 0.31 11 18 11 9.75 8.84 12 67 52
Long-Term Debt		 - - - - - - - - 0.00 50 50
Other Noncurrent Operating Liabilities		 1.78 0.34 0.08 11 18 11 9.75 8.84 12 17 2.49
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 3.22 3.44 27 30 15 46 18 10 158 245 450
Total Preferred & Common Equity		 3.22 3.44 27 30 15 46 18 10 158 245 450
Preferred Stock		 - - - - - - 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 3.22 3.44 27 30 15 46 18 10 158 245 450
Common Stock		 89 102 141 157 173 228 231 248 434 697 881
Retained Earnings		 -86 -98 -114 -127 -158 -182 -213 -237 -276 -452 -431
Accumulated Other Comprehensive Income / (Loss)		 - - - - - - - - 0.00 0.36 0.42

Quarterly Balance Sheets for Soleno Therapeutics

This table presents Soleno Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 32 20 31 64 169 304 297 318 332 600 608
Total Current Assets		 21 9.13 20 54 151 268 258 309 317 535 326
Cash & Equivalents		 20 7.87 19 52 43 57 48 81 76 247 133
Short-Term Investments		 - - - - 107 209 208 209 210 252 123
Accounts Receivable		 - - - - - - - - 25 26 47
Inventories, net		 - - - - - - - - 2.36 6.67 17
Prepaid Expenses		 0.82 1.25 1.13 1.22 1.60 1.38 1.42 19 2.97 3.74 6.33
Plant, Property, & Equipment, net		 0.02 0.02 0.02 0.02 0.03 0.02 0.20 0.17 0.17 0.15 0.20
Total Noncurrent Assets		 11 10 10 9.87 18 37 38 9.00 15 65 282
Long-Term Investments		 - - - - 8.82 28 28 0.00 7.00 57 273
Intangible Assets		 11 10 9.72 9.24 8.26 7.78 7.29 6.32 5.83 5.35 4.37
Other Noncurrent Operating Assets		 0.21 0.18 0.71 0.64 0.50 0.35 3.08 2.69 2.52 2.40 4.05
Total Liabilities & Shareholders' Equity		 32 20 31 64 169 304 297 318 332 600 608
Total Liabilities		 17 17 19 40 25 23 32 86 92 105 113
Total Current Liabilities		 7.34 7.76 8.80 29 13 9.15 15 16 21 33 58
Accounts Payable		 2.32 2.78 3.44 3.22 8.02 3.72 6.24 5.48 6.22 8.15 12
Current Employee Benefit Liabilities		 1.28 0.72 1.17 1.50 1.23 2.15 3.41 4.28 6.27 7.25 5.72
Other Current Liabilities		 0.91 0.73 0.73 21 1.82 1.42 3.55 3.72 6.19 18 40
Total Noncurrent Liabilities		 9.44 9.14 9.72 11 12 14 17 70 71 72 55
Long-Term Debt		 - - - - - - - 50 50 50 50
Other Noncurrent Operating Liabilities		 9.44 9.14 9.72 11 12 14 17 20 21 22 4.67
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 15 2.64 12 23 143 281 265 232 240 495 496
Total Preferred & Common Equity		 15 2.64 12 23 143 281 265 232 240 495 496
Preferred Stock		 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 15 2.64 12 23 143 281 265 232 240 495 496
Common Stock		 247 248 267 288 441 601 660 728 741 969 898
Retained Earnings		 -232 -246 -254 -265 -298 -320 -396 -496 -501 -475 -400
Accumulated Other Comprehensive Income / (Loss)		 -0.00 0.02 0.00 -0.00 -0.11 -0.15 0.90 0.23 0.09 0.36 -1.84

Annual Metrics And Ratios for Soleno Therapeutics

This table displays calculated financial ratios and metrics derived from Soleno Therapeutics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -219.14% 57.48% -76.08% 1.01% -141.96% 19.95% -27.60% 22.61% -76.80% -381.16% 104.17%
EBIT Growth		 -74.66% 57.65% -99.51% -1.73% -121.54% 18.67% -25.45% 21.17% -70.58% -351.50% 105.02%
NOPAT Growth		 -135.67% 31.54% -46.21% -17.50% -64.23% -54.51% 13.12% 22.62% -69.63% -353.49% 107.17%
Net Income Growth		 -20.18% 24.16% -27.52% 13.32% -130.78% 19.94% -25.45% 22.14% -62.00% -351.04% 111.88%
EPS Growth		 83.78% 24.16% 66.27% 62.57% -40.63% 56.67% -1,389.74% 50.60% 17.77% -85.59% 108.90%
Operating Cash Flow Growth		 -129.67% -31.06% 26.29% -17.42% -48.72% -45.17% -10.09% 25.17% -20.01% -177.05% 167.73%
Free Cash Flow Firm Growth		 -66.23% 3.31% -331.82% 109.85% -250.50% -537.10% 19.18% 26.54% -28.86% -469.33% 93.17%
Invested Capital Growth		 -199.82% 39.80% 1,484.30% -67.03% -191.32% 36.45% 4.51% -21.16% -186.18% -94.73% 74.23%
Revenue Q/Q Growth		 65.98% -100.00% 100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 92.96%
EBITDA Q/Q Growth		 -6.39% 49.02% -98.81% 26.93% -87.00% 34.16% 0.09% -15.24% -27.25% -35.65% 108.74%
EBIT Q/Q Growth		 -6.64% 49.07% -92.09% 24.38% -77.05% 32.33% 0.07% -13.82% -25.64% -31.73% 110.54%
NOPAT Q/Q Growth		 -15.82% 30.82% -79.78% 10.42% -15.87% -3.43% 13.58% -11.97% -25.09% -31.73% 115.06%
Net Income Q/Q Growth		 21.56% 1.89% -16.07% 27.29% -93.72% 32.33% 0.08% -12.42% -17.51% -34.07% 126.63%
EPS Q/Q Growth		 16.34% 1.89% 2.29% 25.58% -80.00% 17.02% -228.25% 55.64% 23.13% -61.62% 119.90%
Operating Cash Flow Q/Q Growth		 -21.49% 4.86% -0.43% -9.40% -8.36% -7.64% 0.01% 7.64% -4.93% -34.38% 280.71%
Free Cash Flow Firm Q/Q Growth		 0.00% 45.64% -38.05% 212.39% 67.59% -115.47% 13.44% 12.57% -1,496.55% -10.02% 88.49%
Invested Capital Q/Q Growth		 38.05% -629.82% 15.62% 39.99% -258.09% 54.78% 56.01% 6.53% 58.33% -18.40% 46.51%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 41.94% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 98.58%
EBITDA Margin		 -2,601.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 4.17%
Operating Margin		 -2,001.70% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 4.94%
EBIT Margin		 -2,618.81% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 4.94%
Profit (Net Income) Margin		 -2,618.81% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 10.97%
Tax Burden Percent		 100.00% 179.07% 114.45% 112.62% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.00% 100.00% 100.00% 86.59% 101.58% 100.00% 100.00% 98.77% 93.80% 93.70% 221.90%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 399.40% -362.37% -101.71% -46.60% -135.69% -81.46% -97.60% -171.05% -46.45% -87.35% 6.01%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% -151.56% 22.46% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -191.70% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2.10%
Return on Assets (ROA)		 -191.70% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 4.67%
Return on Common Equity (ROCE)		 399.40% -362.37% -101.71% -46.60% -135.69% -81.46% -97.60% -171.05% -46.45% -87.35% 6.01%
Return on Equity Simple (ROE_SIMPLE)		 -493.47% -351.22% -57.37% -43.85% -205.89% -54.10% -173.72% -232.58% -24.75% -71.74% 0.00%
Net Operating Profit after Tax (NOPAT)		 -8.51 -5.83 -8.52 -10 -16 -25 -22 -17 -29 -131 9.41
NOPAT Margin		 -1,401.19% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 4.94%
Net Nonoperating Expense Percent (NNEP)		 302.44% -120.51% -110.51% -20.99% -63.98% 2.18% -25.07% -38.93% -10.87% -20.29% 3.17%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -165.04% -18.39% -44.54% 1.88%
Cost of Revenue to Revenue		 58.06% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1.42%
SG&A Expenses to Revenue		 1,010.88% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 69.39%
R&D to Revenue		 746.74% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 21.34%
Operating Expenses to Revenue		 2,043.64% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 93.64%
Earnings before Interest and Taxes (EBIT)		 -16 -6.74 -13 -14 -30 -25 -31 -24 -42 -188 9.41
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -16 -6.72 -12 -12 -28 -23 -29 -22 -40 -191 7.95
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.04 0.08 0.59 0.22 0.12 1.56 7.79 7.91 5.52
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.19 0.20 0.00 0.33 0.42 0.00 8.25 8.13 5.59
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 13.06
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 121.45
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.82%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 10.66
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 255.45
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 215.69
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 215.69
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 43.39
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.20 0.11
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.20 0.11
Financial Leverage		 -0.61 -1.55 -0.41 -0.55 -0.99 -1.16 -1.11 -1.28 -1.10 -1.09 -1.04
Leverage Ratio		 -2.08 2.07 1.47 1.44 1.79 1.71 1.59 2.21 1.23 1.27 1.29
Compound Leverage Factor		 -2.08 2.07 1.47 1.24 1.82 1.71 1.59 2.18 1.16 1.19 2.86
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 16.89% 9.97%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 16.89% 9.97%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 83.11% 90.03%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.26 6.27
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.41 -57.39
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.26 6.27
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.38 5.30
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.05 -48.46
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.38 5.30
Altman Z-Score		 0.00 0.00 -4.66 -4.42 -7.67 -4.10 -10.71 -14.60 29.93 10.76 13.07
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 2.01 2.23 10.38 13.14 4.26 5.83 2.80 2.14 14.89 15.68 5.80
Quick Ratio		 1.77 1.60 9.87 12.86 4.18 5.71 2.66 2.00 14.75 15.55 5.44
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -6.98 -6.74 -29 2.87 -4.32 -28 -22 -16 -21 -120 -8.18
Operating Cash Flow to CapEx		 -18,465.19% -91,233.39% -1,730.43% -146,037.50% -82,738.10% -360,342.86% -126,227.27% -159,853.85% 0.00% -31,695.41% 64,106.85%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -518.77 -1.49
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -299.12 8.55
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -300.06 8.53
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.07 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.43
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 1.07 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 8.48 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1,026.44
Accounts Payable Turnover		 0.42 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.25
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 341.70 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 870.30 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1,440.87
Cash Conversion Cycle (CCC)		 -528.59 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1,440.87
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -2.31 -1.39 19 6.34 -5.79 -3.68 -3.51 -4.25 -12 -24 -6.11
Invested Capital Turnover		 -0.40 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -12.77
Increase / (Decrease) in Invested Capital		 -1.54 0.92 21 -13 -12 2.11 0.17 -0.74 -7.92 -12 18
Enterprise Value (EV)		 0.00 0.00 -16 -22 -12 -39 -19 1.55 1,058 1,669 2,031
Market Capitalization		 0.00 0.00 1.20 2.44 8.75 10 2.18 16 1,228 1,938 2,487
Book Value per Share		 $0.26 $0.22 $2.68 $1.42 $0.44 $0.57 $0.22 $1.27 $5.16 $5.68 $8.38
Tangible Book Value per Share		 $0.18 $0.22 $0.64 $0.56 ($0.05) $0.39 $0.06 ($0.04) $4.88 $5.53 $8.29
Total Capital		 3.22 3.44 27 30 15 46 18 10 158 295 500
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 50 50
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 50 50
Net Debt		 -5.53 -2.76 -17 -24 -21 -49 -21 -15 -170 -269 -456
Capital Expenditures (CapEx)		 0.06 0.01 0.58 0.01 0.02 0.01 0.02 0.01 0.00 0.22 0.07
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -2.32 -0.67 -0.87 -1.28 -4.55 -7.60 -6.89 -6.27 -9.83 -16 -11
Debt-free Net Working Capital (DFNWC)		 3.21 2.09 16 23 16 42 14 8.33 160 275 294
Net Working Capital (NWC)		 3.21 2.09 16 23 16 42 14 8.33 160 275 294
Net Nonoperating Expense (NNE)		 7.40 6.24 6.87 3.32 14 -0.76 8.84 6.99 10 44 -11
Net Nonoperating Obligations (NNO)		 -5.53 -4.82 -7.60 -24 -21 -49 -21 -15 -170 -269 -456
Total Depreciation and Amortization (D&A)		 0.11 0.02 1.61 1.96 1.96 1.95 1.96 1.96 1.96 -2.91 -1.47
Debt-free, Cash-free Net Working Capital to Revenue		 -381.57% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -5.79%
Debt-free Net Working Capital to Revenue		 528.68% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 154.64%
Net Working Capital to Revenue		 528.68% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 154.64%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($126.75) ($75.75) ($26.25) ($9.60) ($13.50) ($5.85) ($5.85) ($2.87) ($2.36) ($4.38) $0.40
Adjusted Weighted Average Basic Shares Outstanding		 205.40K 633.07K 1.30M 2.12M 2.98M 5.31M 5.34M 8.40M 16.49M 40.18M 50.82M
Adjusted Diluted Earnings per Share		 ($126.75) ($75.75) ($26.25) ($9.60) ($13.50) ($5.85) ($5.85) ($2.87) ($2.36) ($4.38) $0.39
Adjusted Weighted Average Diluted Shares Outstanding		 205.40K 633.07K 1.30M 2.12M 2.98M 5.31M 5.34M 8.40M 16.49M 40.18M 52.38M
Adjusted Basic & Diluted Earnings per Share		 ($126.75) ($75.75) ($26.25) ($9.60) ($13.50) ($5.85) ($5.85) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 125.68K 206.77K 598.52K 1.40M 2.28M 4.17M 5.32M 8.17M 32.46M 45.86M 51.62M
Normalized Net Operating Profit after Tax (NOPAT)		 -8.51 -5.83 -8.52 -10 -16 -25 -22 -17 -29 -131 6.59
Normalized NOPAT Margin		 -1,401.19% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 3.46%
Pre Tax Income Margin		 -2,618.81% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 10.97%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -812.43 1.72
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -568.70 1.72
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -813.37 1.71
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -569.64 1.71
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 479.40%

Quarterly Metrics And Ratios for Soleno Therapeutics

This table displays calculated financial ratios and metrics derived from Soleno Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - - - - - 51,624,384.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 51,624,384.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - 0.61
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -86.97% -153.32% -194.00% -213.38% -674.03% -347.16% -96.99% 72.58% 127.25% 164.82% 168.34%
EBIT Growth		 -79.96% -140.41% -177.19% -188.43% -626.89% -324.99% -94.86% 73.76% 127.56% 166.95% 168.38%
NOPAT Growth		 -66.51% -147.95% -177.19% -188.39% -672.61% -324.99% -94.86% 73.76% 139.37% 195.64% 187.79%
Net Income Growth		 -77.12% -105.91% -156.08% -157.86% -605.42% -395.59% -104.57% 78.46% 133.95% 177.45% 171.68%
EPS Growth		 -46.15% 165.12% 32.95% 29.63% -92.63% -596.43% -61.02% 84.21% 125.68% 169.06% 162.11%
Operating Cash Flow Growth		 -36.00% -22.77% -86.21% -217.12% -135.72% -279.97% -161.43% 28.57% 391.13% 303.01% 179.32%
Free Cash Flow Firm Growth		 323.19% 42.93% -111.22% -268.34% -475.57% -1,542.72% -500.29% -42.52% 120.67% 173.64% 110.07%
Invested Capital Growth		 -541.99% -186.18% -187.72% -99.48% 31.47% -94.73% 50.67% 75.09% 42.95% 74.23% 324.63%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 102.16% 38.95% 3.13%
EBITDA Q/Q Growth		 -29.66% -27.27% -74.79% -8.65% -220.25% 26.47% 23.00% 84.88% 418.33% 74.88% -18.83%
EBIT Q/Q Growth		 -27.99% -26.05% -68.76% -5.93% -222.55% 26.30% 22.62% 85.74% 438.77% 79.04% -20.97%
NOPAT Q/Q Growth		 -20.40% -33.98% -68.76% -5.93% -222.55% 26.30% 22.62% 85.74% 583.96% 79.04% -28.97%
Net Income Q/Q Growth		 -28.15% -4.01% -89.43% -2.13% -250.58% 26.93% 21.81% 89.24% 652.53% 66.68% -27.63%
EPS Q/Q Growth		 -17.28% 129.47% -310.71% 3.39% -221.05% 24.04% 31.65% 90.53% 622.22% 104.26% -38.54%
Operating Cash Flow Q/Q Growth		 -13.76% 0.28% -98.42% -40.89% 15.44% -60.73% -36.52% 61.50% 444.65% 12.08% -46.66%
Free Cash Flow Firm Q/Q Growth		 710.24% -110.44% -263.54% -58.98% -522.22% 54.32% -32.85% 62.26% 190.24% 62.74% -81.84%
Invested Capital Q/Q Growth		 -320.87% 58.33% -23.72% 8.06% -44.58% -18.40% 68.66% 53.58% -231.20% 46.51% 373.16%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 97.87% 98.27% 99.06% 98.73%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -21.40% 33.70% 42.41% 33.38%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -19.98% 33.48% 43.15% 33.06%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -19.98% 33.48% 43.15% 33.06%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -14.42% 39.40% 47.27% 33.17%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 89.87%
Interest Burden Percent		 98.42% 81.21% 91.15% 87.88% 95.52% 94.70% 95.69% 72.15% 117.68% 109.55% 111.62%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 10.13%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1,829.15%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1,828.24%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,804.98%
Return on Equity (ROE)		 -172.71% -46.45% -71.26% -44.62% -91.11% -87.35% -105.54% -69.53% -20.66% 6.01% 24.16%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 373.37%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -2.05% 7.37% 18.36% 20.34%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1.48% 8.67% 20.12% 20.41%
Return on Common Equity (ROCE)		 -172.71% -46.45% -71.26% -44.62% -91.11% -87.35% -105.54% -69.53% -20.66% 6.01% 24.16%
Return on Equity Simple (ROE_SIMPLE)		 -142.89% 0.00% -36.29% -23.30% -49.55% 0.00% -85.35% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -7.27 -9.74 -16 -17 -56 -41 -32 -4.57 22 40 28
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -13.99% 33.48% 43.15% 29.71%
Net Nonoperating Expense Percent (NNEP)		 -9.96% -1.69% -5.97% -2.83% -12.14% -6.66% -5.90% -0.05% 0.99% 1.04% 0.91%
Return On Investment Capital (ROIC_SIMPLE)		 - -6.18% - - - -14.03% -11.35% -1.58% 4.06% 7.92% 5.15%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2.13% 1.73% 0.94% 1.27%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 86.47% 51.13% 44.56% 53.24%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 28.01% 12.73% 10.42% 11.92%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 117.85% 64.79% 55.91% 65.67%
Earnings before Interest and Taxes (EBIT)		 -11 -14 -23 -25 -80 -59 -46 -6.53 22 40 31
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -11 -13 -23 -25 -82 -60 -46 -6.99 22 39 32
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 12.70 7.79 9.69 4.86 7.41 7.91 14.11 17.58 7.26 5.52 3.49
Price to Tangible Book Value (P/TBV)		 21.08 8.25 10.28 4.99 7.62 8.13 14.50 18.02 7.34 5.59 3.52
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 129.28 36.41 13.06 6.06
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 121.45 18.07
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.82% 5.53%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 74.85
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 121.81 31.28 10.66 4.38
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 255.45 14.57
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 215.69 14.45
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 215.69 14.45
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 43.39 11.84
Enterprise Value to Free Cash Flow (EV/FCFF)		 160.85 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 20.05
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.20 0.21 0.21 0.10 0.11 0.10
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.20 0.21 0.21 0.10 0.11 0.10
Financial Leverage		 -1.88 -1.10 -1.14 -1.07 -1.17 -1.09 -1.06 -1.03 -1.04 -1.04 -0.99
Leverage Ratio		 2.49 1.23 1.29 1.14 1.25 1.27 1.30 1.22 1.18 1.29 1.27
Compound Leverage Factor		 2.45 1.00 1.18 1.00 1.20 1.20 1.24 0.88 1.39 1.41 1.42
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 16.89% 17.67% 17.19% 9.15% 9.97% 9.14%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 16.89% 17.67% 17.19% 9.15% 9.97% 9.14%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 83.11% 82.33% 82.81% 90.85% 90.03% 90.86%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 -0.26 -0.23 -0.26 -0.55 6.27 0.58
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 1.41 1.13 1.25 5.57 -57.39 -5.59
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 -0.26 -0.23 -0.26 -0.55 6.27 0.58
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 -0.38 -0.34 -0.37 -0.80 5.30 0.58
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 2.05 1.63 1.82 8.10 -48.46 -5.54
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 -0.38 -0.34 -0.37 -0.80 5.30 0.58
Altman Z-Score		 -1.56 30.44 30.80 34.27 35.01 12.04 21.35 26.48 20.69 13.25 9.46
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 1.85 14.89 11.23 29.24 17.26 15.68 19.64 15.13 16.08 5.80 5.62
Quick Ratio		 1.81 14.75 11.11 29.08 17.16 15.55 18.43 14.87 15.77 5.44 5.22
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 17 -1.82 -6.61 -11 -65 -30 -40 -15 14 22 3.99
Operating Cash Flow to CapEx		 0.00% 0.00% -113,890.91% -220,637.50% -7,814.66% -299,887.50% -655,040.00% -140,088.89% 4,345,400.00% 83,972.41% 64,950.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -29.13 -10.88 9.72 16.29 3.09
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -24.06 -9.16 31.26 36.10 20.11
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -24.07 -9.17 31.26 36.06 20.08
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.10 0.22 0.43 0.62
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 353.05 570.38 1,026.44 1,520.04
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.14 0.26 0.25 0.44
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2,604.30 1,429.40 1,440.87 836.61
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -2,604.30 -1,429.40 -1,440.87 -836.61
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -29 -12 -15 -14 -20 -24 -7.43 -3.45 -11 -6.11 17
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -3.78 -6.28 -12.77 61.56
Increase / (Decrease) in Invested Capital		 -25 -7.92 -9.83 -6.91 9.20 -12 7.63 10 8.60 18 24
Enterprise Value (EV)		 242 1,058 1,231 1,069 1,678 1,669 3,036 3,978 3,086 2,031 1,249
Market Capitalization		 295 1,228 1,389 1,363 1,963 1,938 3,277 4,222 3,593 2,487 1,728
Book Value per Share		 $2.32 $5.16 $4.42 $8.40 $6.81 $5.68 $5.06 $4.77 $9.31 $8.38 $9.60
Tangible Book Value per Share		 $1.40 $4.88 $4.16 $8.17 $6.62 $5.53 $4.93 $4.65 $9.21 $8.29 $9.52
Total Capital		 23 158 143 281 265 295 282 290 545 500 546
Total Debt		 0.00 0.00 0.00 0.00 0.00 50 50 50 50 50 50
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 50 50 50 50 50 50
Net Debt		 -52 -170 -158 -295 -285 -269 -240 -244 -506 -456 -479
Capital Expenditures (CapEx)		 0.00 0.00 0.01 0.01 0.19 0.01 0.01 0.01 0.00 0.06 0.04
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -28 -9.83 -12 -7.77 -14 -16 3.23 9.01 2.67 -11 13
Debt-free Net Working Capital (DFNWC)		 25 160 138 258 243 275 293 296 502 294 268
Net Working Capital (NWC)		 25 160 138 258 243 275 293 296 502 294 268
Net Nonoperating Expense (NNE)		 3.59 1.56 4.97 4.45 20 15 12 0.14 -3.91 -3.78 -3.27
Net Nonoperating Obligations (NNO)		 -52 -170 -158 -295 -285 -269 -240 -244 -506 -456 -479
Total Depreciation and Amortization (D&A)		 0.49 0.49 0.02 -0.62 -1.41 -0.90 -0.47 -0.46 0.14 -0.67 0.30
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 27.57% 2.70% -5.79% 4.47%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 905.92% 508.34% 154.64% 94.15%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 905.92% 508.34% 154.64% 94.15%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.95) $0.28 ($0.59) ($0.57) ($1.83) ($1.39) ($0.95) ($0.09) $0.49 $0.95 $0.60
Adjusted Weighted Average Basic Shares Outstanding		 11.44M 16.49M 36.21M 38.63M 41.88M 40.18M 46.18M 50.48M 53.33M 50.82M 52.09M
Adjusted Diluted Earnings per Share		 ($0.95) $0.28 ($0.59) ($0.57) ($1.83) ($1.39) ($0.95) ($0.09) $0.47 $0.96 $0.59
Adjusted Weighted Average Diluted Shares Outstanding		 11.44M 16.49M 36.21M 38.63M 41.88M 40.18M 46.18M 50.48M 54.92M 52.38M 53.07M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 30.50M 32.46M 33.41M 38.87M 43.12M 45.86M 50.39M 53.15M 53.71M 51.62M 52.12M
Normalized Net Operating Profit after Tax (NOPAT)		 -7.27 -9.74 -16 -17 -56 -41 -32 -4.57 15 28 28
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -13.99% 23.44% 30.20% 29.71%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -14.42% 39.40% 47.27% 36.90%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -33.61 -4.74 15.90 29.34 24.21
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -23.53 -3.32 15.90 29.34 21.76
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -33.61 -4.75 15.90 29.30 24.18
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -23.53 -3.33 15.90 29.30 21.73
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 479.40% 104.28%

Financials Breakdown Chart

Key Financial Trends

Soleno Therapeutics (SLNO) has shown a notable pivot in late-2025, with improving profitability and liquidity signals alongside ongoing investment activity. Below are the key takeaways based on the last four years of quarterly statements.

  • Strong Q4 2025 profitability: Net income from continuing operations of about $43.36 million, following positive results in Q3 2025 as well.
  • High gross margin in Q4 2025: Total Revenue of $91.73 million with Total Gross Profit of $90.87 million (very large gross margin for the quarter).
  • Operating cash flow improving in late 2025: Net cash from continuing operating activities of $48.70 million in Q4 2025 and $43.45 million in Q3 2025.
  • Strong liquidity position (mid-2025): Cash & equivalents around $246.66 million and short-term investments around $252.27 million, with total current assets about $534.85 million and total assets near $599.90 million.
  • Active equity financing support in 2025: Issuance of Common Equity of about $215.72 million in Q3 2025, contributing to robust net financing activity and liquidity.
  • Revenue history is volatile: Several prior quarters (notably 2022–2024) show zero or very low revenue, indicating an uneven revenue trajectory prior to the 2025 uptick.
  • Equity composition vs. earnings: Large common equity balances alongside negative retained earnings across periods, signaling ongoing losses but a positive aggregate equity base.
  • Persistent net losses through 2024: Notable negatives include 2024 Q4 net income of about −$55.98 million, 2024 Q3 net income of about −$76.62 million, and other mid-year losses (e.g., Q2 2024 −$21.85 million, Q1 2024 −$21.40 million).
  • Investing cash outflows remain material: Recurrent heavy cash outlays for investments, such as about −$125.36 million in Q4 2025 and Q1 2025, and around −$91.44 million in Q3 2025, weighing on near-term cash burn.
  • cumulated losses reflected in negative retained earnings: As of several quarters, retained earnings run negative (e.g., −$474.7 million in Q3 2025 and around −$500+ million in earlier periods), underscoring ongoing profitability challenges despite strong quarterly positives.
05/18/26 11:47 AM ETAI Generated. May Contain Errors.

Soleno Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Soleno Therapeutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Soleno Therapeutics' net income appears to be on an upward trend, with a most recent value of $20.89 million in 2025, falling from -$15.91 million in 2015. The previous period was -$175.85 million in 2024. See Soleno Therapeutics' forecast for analyst expectations on what's next for the company.

Soleno Therapeutics' total operating income in 2025 was $9.41 million, based on the following breakdown:
  • Total Gross Profit: $187.71 million
  • Total Operating Expenses: $178.29 million

Over the last 10 years, Soleno Therapeutics' total revenue changed from $607.47 thousand in 2015 to $190.41 million in 2025, a change of 31,243.8%.

Soleno Therapeutics' total liabilities were at $113.72 million at the end of 2025, a 32.4% increase from 2024, and a 2,184.6% increase since 2015.

In the past 10 years, Soleno Therapeutics' cash and equivalents has ranged from $2.73 million in 2016 to $169.68 million in 2023, and is currently $70.11 million as of their latest financial filing in 2025.

Over the last 10 years, Soleno Therapeutics' book value per share changed from 0.26 in 2015 to 8.38 in 2025, a change of 3,114.6%.


Related Companies

Financial statements for NASDAQ:SLNO last updated on 5/8/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
If You Have $50k+ on Coinbase, This Will Ruin Your Day
I spent two years reverse-engineering BlackRock's exact playbook. The same framework that generates them $16.1...
Decentralized Masters | Sponsoredtc pixel
Musk’s warning just revealed a $1T opportunity
Elon Musk recently warned that AI could force governments to introduce universal income. Mode Mobile isn't wai...
Mode Mobile | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
ZENA Surges: 558% Revenue Growth Fuels Breakout Small-Cap Narrative!
ZenaTech (NASDAQ: ZENA) reported $12.9 million in full-year 2025 revenue, representing 558% year-over-year gro...
Equiscreen | Sponsoredtc pixel
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel
Your book attached
Veteran trader Bill Poulos is giving away his 'Simple Options Trading For Beginners' book - normally $29.97 - ...
Profits Run | Sponsoredtc pixel